194 related articles for article (PubMed ID: 36603729)
21. A GPC3-specific aptamer-mediated magnetic resonance probe for hepatocellular carcinoma.
Zhao M; Liu Z; Dong L; Zhou H; Yang S; Wu W; Lin J
Int J Nanomedicine; 2018; 13():4433-4443. PubMed ID: 30122918
[TBL] [Abstract][Full Text] [Related]
22. MR characterisation of dysplastic nodules and hepatocarcinoma in the cirrhotic liver with hepatospecific superparamagnetic contrast agents: pathological correlation in explanted livers.
Macarini L; Milillo P; Cascavilla A; Scalzo G; Stoppino L; Vinci R; Moretti G; Ettorre G
Radiol Med; 2009 Dec; 114(8):1267-82. PubMed ID: 19902328
[TBL] [Abstract][Full Text] [Related]
23. Hepatocellular carcinoma in cirrhotic livers: detection with unenhanced and iron oxide-enhanced MR imaging.
Yamamoto H; Yamashita Y; Yoshimatsu S; Baba Y; Hatanaka Y; Murakami R; Nishiharu T; Takahashi M; Higashida Y; Moribe N
Radiology; 1995 Apr; 195(1):106-12. PubMed ID: 7892448
[TBL] [Abstract][Full Text] [Related]
24. Liver transplantation in cirrhotic patients with small hepatocellular carcinoma: an analysis of pre-operative imaging, explant histology and prognostic histologic indicators.
Bhattacharjya S; Bhattacharjya T; Quaglia A; Dhillon AP; Burroughs AK; Patch DW; Tibballs JM; Watkinson AF; Rolles K; Davidson BR
Dig Surg; 2004; 21(2):152-9; discussion 159-60. PubMed ID: 15166485
[TBL] [Abstract][Full Text] [Related]
25. How to detect hepatocellular carcinoma in cirrhosis.
Ward J; Robinson PJ
Eur Radiol; 2002 Sep; 12(9):2258-72. PubMed ID: 12195479
[TBL] [Abstract][Full Text] [Related]
26. Collagenase-I decorated co-delivery micelles potentiate extracellular matrix degradation and hepatic stellate cell targeting for liver fibrosis therapy.
Zhou L; Liang Q; Li Y; Cao Y; Li J; Yang J; Liu J; Bi J; Liu Y
Acta Biomater; 2022 Oct; 152():235-254. PubMed ID: 36087869
[TBL] [Abstract][Full Text] [Related]
27. Glypican-3 targeting of liver cancer cells using multifunctional nanoparticles.
Park JO; Stephen Z; Sun C; Veiseh O; Kievit FM; Fang C; Leung M; Mok H; Zhang M
Mol Imaging; 2011 Feb; 10(1):69-77. PubMed ID: 21303616
[TBL] [Abstract][Full Text] [Related]
28. Targeting monocyte-intrinsic enhancer reprogramming improves immunotherapy efficacy in hepatocellular carcinoma.
Liu M; Zhou J; Liu X; Feng Y; Yang W; Wu F; Cheung OK; Sun H; Zeng X; Tang W; Mok MTS; Wong J; Yeung PC; Lai PBS; Chen Z; Jin H; Chen J; Chan SL; Chan AWH; To KF; Sung JJY; Chen M; Cheng AS
Gut; 2020 Feb; 69(2):365-379. PubMed ID: 31076403
[TBL] [Abstract][Full Text] [Related]
29. Expression of glypican 3 enriches hepatocellular carcinoma development-related genes and associates with carcinogenesis in cirrhotic livers.
Liu X; Wang SK; Zhang K; Zhang H; Pan Q; Liu Z; Pan H; Xue L; Yen Y; Chu PG
Carcinogenesis; 2015 Feb; 36(2):232-42. PubMed ID: 25542894
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of antiglypican-3 therapy as a promising target for amelioration of hepatic tissue damage in hepatocellular carcinoma.
Zaghloul RA; El-Shishtawy MM; El Galil KH; Ebrahim MA; Metwaly AA; Al-Gayyar MM
Eur J Pharmacol; 2015 Jan; 746():353-62. PubMed ID: 25449037
[TBL] [Abstract][Full Text] [Related]
31. Peptide Binder to Glypican-3 as a Theranostic Agent for Hepatocellular Carcinoma.
Lin F; Clift R; Ehara T; Yanagida H; Horton S; Noncovich A; Guest M; Kim D; Salvador K; Richardson S; Miller T; Han G; Bhat A; Song K; Li G
J Nucl Med; 2024 Apr; 65(4):586-592. PubMed ID: 38423788
[TBL] [Abstract][Full Text] [Related]
32. Evolution of indeterminate hepatocellular nodules at Gd-EOB-DPTA-enhanced MRI in cirrhotic patients.
Galia M; Agnello F; Sparacia G; Matranga D; Albano D; Midiri M; Lagalla R
Radiol Med; 2018 Jul; 123(7):489-497. PubMed ID: 29546493
[TBL] [Abstract][Full Text] [Related]
33. Roles of Combined Glypican-3 and Glutamine Synthetase in Differential Diagnosis of Hepatocellular Lesions.
Wasfy RE; Shams Eldeen AA
Asian Pac J Cancer Prev; 2015; 16(11):4769-75. PubMed ID: 26107238
[TBL] [Abstract][Full Text] [Related]
34. Imaging of dysplastic nodules and small hepatocellular carcinomas: experience with explanted livers.
Krinsky G
Intervirology; 2004; 47(3-5):191-8. PubMed ID: 15383729
[TBL] [Abstract][Full Text] [Related]
35. Preparation of magnetic resonance probes using one-pot method for detection of hepatocellular carcinoma.
Li YW; Chen ZG; Zhao ZS; Li HL; Wang JC; Zhang ZM
World J Gastroenterol; 2015 Apr; 21(14):4275-83. PubMed ID: 25892879
[TBL] [Abstract][Full Text] [Related]
36. Glypican-3: a marker and a therapeutic target in hepatocellular carcinoma.
Filmus J; Capurro M
FEBS J; 2013 May; 280(10):2471-6. PubMed ID: 23305321
[TBL] [Abstract][Full Text] [Related]
37. Glypican-3: A promising biomarker for hepatocellular carcinoma diagnosis and treatment.
Zhou F; Shang W; Yu X; Tian J
Med Res Rev; 2018 Mar; 38(2):741-767. PubMed ID: 28621802
[TBL] [Abstract][Full Text] [Related]
38. Value of contrast-enhanced intraoperative ultrasound for cirrhotic patients with hepatocellular carcinoma: a report of 20 cases.
Lu Q; Luo Y; Yuan CX; Zeng Y; Wu H; Lei Z; Zhong Y; Fan YT; Wang HH; Luo Y
World J Gastroenterol; 2008 Jul; 14(25):4005-10. PubMed ID: 18609684
[TBL] [Abstract][Full Text] [Related]
39. Promoting Early Diagnosis and Precise Therapy of Hepatocellular Carcinoma by Glypican-3-Targeted Synergistic Chemo-Photothermal Theranostics.
Mu W; Jiang D; Mu S; Liang S; Liu Y; Zhang N
ACS Appl Mater Interfaces; 2019 Jul; 11(26):23591-23604. PubMed ID: 31179679
[TBL] [Abstract][Full Text] [Related]
40. H-rGO-Pd NPs Nanozyme Enhanced Silver Deposition Strategy for Electrochemical Detection of Glypican-3.
Li G; Wang B; Li L; Li X; Yan R; Liang J; Zhou X; Li L; Zhou Z
Molecules; 2023 Feb; 28(5):. PubMed ID: 36903516
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
